(AGEPC'), the semi-synthetic platelet activating factor (Demopoulos o/ (I/.. 1979) . This varying pattern of reaction may bc attributed to differences in target-cell sensitivities and or to difl'erences in the anatomical distribution o f target cclls and organs (Vargaftig ot d . , 1983) .
We havc rcccntly shown that mice are highly resistant t o AGEPC and they develop the anaphylactic reaction very slowly. We have furthermore shown that mouse platelets arc highly refractory to the action of AGEPC in vitro. (Lanara c't d . . 1982) . These findings combined with the known sensitivity of mice to the biogenic amines (Halpern cf d . . 1963) prompted us to use a series of antagonists to investigate the nature of the mediators released in the AGEPC-effected anaphylactic reaction in mice. Specifically we studied indomethacin and sulphinpyrazone, non-steroidal anti-inflammatory drugs. inhibitors of arachidonate metabolism through the cyclooxygenase pathway. promethazine, and anti-histamine, and chlorpromazine. an anti-serotonin drug. for their ability to ameliorate the effects of a lethal dose of AGEPC o n mice. Changes in haemoconcentration, measured as changes in red blood cell count. leucopenia, thrombocytopenia and survival were measured in male VAKl RT7.1-LEMONIAS Sulphinpyrazone. contrary to indomethacin. very effectively decreases mortality in mice without changing haemoconcentration caused by AGEPC 5 min postchallenge. I t increases leucocyte count ( P > 0.05, 10 min after treatment). which persists 5 min post-AGEPC challenge and also causes thrombocytopenia 90 s postchallenge ( P < 0.05). These findings agree in general with those reported for the guinea pig. In this species sulphinpyrazone suppressed bronchoconstriction without affecting thrombocytopenia. and it was suggested that it exerts a specific, cyclo-oxygenase-independent protective effect towards a platelet activation by AGEPC (Chignard et NI.. 1982). Mouse platelets are. however. refractory to AGEPC and the mechanism by which this drug acts on mice needs further experimentation.
Promethazine, even at a low dose. and chloropromazine significantly decrease the mortality of mice challenged with AGEPC while not affect AGEPCinduced haemoconcentration. The two drugs, adminisTablc I . Effi~ct of'non-stcroiiltrl trtiti-infitimmutorI. drugs on tlir survivirl of'niicv injcctcd with ir Ii~tlicrl (/oso (?J' AG EPC Administcrcd volumes wcrc 0 . I 0.2 ml for intravenous, and 0.2-0.5 ml for intramuscular. intraperitoneal or subcutaneous injections. Indomethacin (4 x SOpg/animal) was given over a 48 h period, sulphinpyramne I0 min bcforc AGEPC and thc low dose of promcthazinc chlorproma7inc and their mixture 30min bcforc AGEPC. *Significantly different ( P < 0.05) is also thc cffect of thc combined drugs (3) as compared with that of each drug administered separately ( I or 7). tered together. have a clear synergistic efyect ( P < 0.05) in decreasing mortality and cause a fall in red blood cell count ( P < 0.05 at 30min) which. however. is overcome by AGEPC. Each drug alone or in combination cause significant leucopenia ( P < 0.01 0.05 at 30min). However, the leucopenia caused by promethazine persists for 5 min post-challenge. that caused by chloropromaiine for 90 s, while the leucopenia caused by the combination of the two drugs cannot be detected even 9 0 s post-A G EPC challenge .
The results show that the biogenic amines appear to play an important role in the development of the AGEPC-elicited anaphylactic reaction in mice. The synergistic action of the two antagonists agrees with the amelioration of the effects of passive cutaneous anaphylaxis and cappilary permeability caused by histamine and serotonin in mice (Halpern (it ul.. 1963) The activity of 5-aminolaevulinate dehydratase. (ALA-D) , the second enzyme in the haem biosynthetic pathway, has been shown to be reduced in the erythrocytes of epileptic patients receiving tre2tment with the anticonvulsant drug. carbamazepine (CBZ) (McGuire e t ul., 1985) . This depression o f ALA-D activity is of interest because i t represents a potential partial block in the pathway. particularly in individuals who may already have a deficiency o f this enzyme due to other factors. such as lead poisoning (Mauras & Allain, 1979) or alcoholism (Kondo et ul.. 1983) . and may be the precipitating factor in the acute porphyric syndrome reported by Yeung et 01. (1983) . The effect has been shown to be irreversible and attempts to reproduce the reduction in ALA-D activity in vitro by direct addition of CBZ and its principal metabolite, carbamazepine-10, I 1-epoxide (CBZ-E), to erythrocytes have been unsuccessful. The objective of this study has been to investigate what effect CBZ and CBZ-E had on ALA-D in metabolically active cultured human lymphocytes as opposed to inert erythrocytes.
ALA-D activity was measured in 7.5 x 10' mitogenstimulated human lymphocytes by the method of Sassa (1982) . Cells were cultured at a density o f 0.75 x IOh cells/ml in R P M l 1640 medium supplemented with 2mM-glutamine and 10% foetal calf serum for 9 6 h before determination of enzyme activity. CBZ and CBZ-E were added in lop1 of dimethylsulphoxide (DMSO). DMSO alone was added to control cultures. Cell viability, a s judged by the exclusion of Trypan Blue. was unaffected at the drug concentrations used. Both CBZ and CBZ-E reduced ALA-D activity. but CBZ-E was the more potent: 3Opg o f CBZlml reduced activity by 16.5% ( n = 7. P < 0.000l) whereas 15pg o f CBZ-El'ml reduced activity by 78% ( n = 6. P < 0.0001). However, in man, both probably make a signiticant contribution to the depression of ALA-D activity ;is CBZ-E accounts for only 10 30% of the total circulating levels of the drug. The epoxide was used in further experiments to determine the effects of dose and exposure time to the drug on the enzyme and this data is presented in Table 1 .
The first part of Table I demonstrates that the extent of the reduction in ALA-D activity was governed by the concentration of CBZ-E in the medium and that efyects were found at pharmacological concentrations of this Table I 
